Healthcare / BiotechnologyNasdaqCM
$1.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-4.2M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$27M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-71.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-7.9M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | $509589.00 | $152430.00 | $969783.00 | $355797.00 | $483045.00 | $701719.00 | $6956.00 | — | — | $3360.00 | — | $7787.00 | $5714.00 | $3190.00 | $14860.00 |
| Net Income | $-7.9M | $-7.9M | $-4.9M | $-7.8M | $-16.4M | $-12.8M | $-10.6M | $-3.9M | $-6.1M | $-4.2M | $-11.0M | $-32281.00 | $-23235.00 | $-226352.00 | $-1.1M | $-1.2M | $-1.9M |
| EBITDA | — | — | — | — | $-15.1M | $-11.7M | — | — | — | — | — | — | — | $-153400.00 | $-1.1M | $-1.9M | $-1.8M |
| EPS | -0.39 | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 | -0.50 | — | -0.02 | -0.02 | -0.06 | — | — | — | — | — | — |
| Gross Margin | — | — | 99.9% | -98.1% | 70.5% | 98.6% | 96.1% | 97.1% | -2563.6% | — | — | 84.5% | — | — | — | — | — |
| Operating Margin | — | — | -923.3% | -4439.2% | -1558.5% | -3290.1% | -1760.9% | -492.9% | -40031.1% | — | — | — | — | -2276.3% | -20004.3% | -59180.7% | -12715.2% |
| Net Margin | — | — | -962.1% | -5109.3% | -1693.5% | -3608.5% | -2193.1% | -560.5% | -87184.2% | — | — | -960.7% | — | -2906.8% | -18718.6% | -38202.2% | -12793.1% |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | — | — | — | $-4.2M | $-7.5M | $-7.6M | — | — | — | — | — | — | — | $-37768.00 | $-915474.00 | $-1.6M | $-1.0M |
| Returns | |||||||||||||||||
| ROE | -71.2% | -71.2% | -399.9% | -501.1% | -530.0% | -145.2% | -308.1% | 2605.4% | 107.2% | 241.5% | 172.6% | -5.1% | -74.1% | 12.0% | 65.1% | 83.3% | 63.5% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | 234.3% | -84.3% | 172.6% | -26.3% | -31.2% | 9988.0% | — | — | — | — | — | 36.3% | 79.1% | -78.5% | — |
| EPS Growth | 7.1% | 7.1% | 76.7% | 65.3% | -917.6% | -2.0% | — | — | 0.0% | 66.7% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.